The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).
S. P. Chawla
Consultant or Advisory Role - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme
J. Blay
Consultant or Advisory Role - ARIAD; Merck Sharp & Dohme
Honoraria - ARIAD; Merck Sharp & Dohme
Research Funding - ARIAD
I. L. Ray-Coquard
No relevant relationships to disclose
A. Le Cesne
No relevant relationships to disclose
A. P. Staddon
Honoraria - ARIAD
Research Funding - ARIAD; Merck Sharp & Dohme
M. M. Milhem
No relevant relationships to disclose
N. Penel
No relevant relationships to disclose
R. F. Riedel
Consultant or Advisory Role - Merck Sharp & Dohme
Honoraria - ARIAD
Research Funding - ARIAD
B. Bui Nguyen
No relevant relationships to disclose
L. D. Cranmer
Research Funding - Merck Sharp & Dohme
P. Reichardt
No relevant relationships to disclose
E. Bompas
No relevant relationships to disclose
Y. Song
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
R. Lee
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
J. E. Eid
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck Sharp & Dohme
J. Loewy
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
F. G. Haluska
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
P. F. Dodion
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
G. D. Demetri
Consultant or Advisory Role - Alnylam; Amgen; ARIAD; ArQule; Bayer; Champions Biotechnology; Daiichi Sankyo; EMD Serono; Enzon; Genentech; GlaxoSmithKline; Idera Pharmaceuticals; Infinity; Johnson & Johnson; Kolltan Pharmaceuticals; N-of-One (U); Novartis; Pfizer; Plexxikon; Takeda; ZIOPHARM Oncology
Stock Ownership - Champions Biotechnology; Kolltan Pharmaceuticals; N-of-One
Honoraria - Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; Infinity; Johnson & Johnson; Novartis; Pfizer
Expert Testimony - ARIAD (U)